Market
Additive Manufacturing Adhesives & Sealants Aerospace Agriculture Animal Nutrition & Health Automotive & Transportation Battery Building, Construction & Infrastructure Catalysts Chemical Industry Circular Economy Coatings, Paints & Printing Composites Consumer Goods & Lifestyle Electronics & Telecommunications Energy, Environment & Utilities Food & Beverage Green Hydrogen Home Care & Cleaning Industrial Manufacturing & Machinery Lubricants & Lubricant Additives Medical Devices Metals & Mining Oil & Gas, Petrochemicals Personal Care & Beauty Pharma & Biopharma Plastics & Rubber Pulp, Paper & Packaging Textiles, Leather & Nonwovens
About Evonik
What drives us
We go beyond Purpose Innovation Circularity BVB Partnership History
Structure & Organization
Executive Board Supervisory Board Segments Business Lines ESHQ Procurement Governance & Compliance Facts & Figures General Conditions of Sale and Delivery (GTC)
Business Lines Career Investor Relations
Alternative image
SHARE
Press Release
Back
Products

March 19, 2025

World’s first medical-grade post-treatment care epicite® CALM for energy-based aesthetic treatments to launch at AMWC Monaco

  • World’s first post-treatment dressing made from biosynthetic cellulose in medical device quality
  • New standard of care following laser, light, and energy-based treatments
  • Sterile option for treatment-prone skin to mitigate liability risks
JeNaCell, an Evonik company, will launch epicite® CALM at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29. Establishing a new gold standard of care in medical aesthetics, epicite® CALM provides optimal post-treatment recovery following laser, light, and energy-based treatments, including fractional CO2 lasers and radiofrequency microneedling.

As the world’s first medical-grade dressing made from biosynthetic cellulose, epicite® CALM will be certified under European Medical Device Regulation (MDR) standards. It offers a safe, sterile, and hypoallergenic option that promotes wound healing while improving patient safety and comfort.

“Biosynthetic cellulose is a material showing superb versatility. Drawing on the extensive clinical experience in treating burns and chronic wounds with products from the epicite® family, we are very pleased to offer epicite® CALM to medical professionals in aesthetics to improve patient outcomes,” said Dr. Dana Kralisch, General Manager of JeNaCell. The Evonik company is a specialist in producing medical-grade products for advanced wound care.

A hydro-active wound dressing, epicite® CALM is designed to create a moist wound environment that promotes healing and minimizes downtime following aesthetic treatments that utilize energy-based technologies, such as CO2 lasers and radiofrequency (RF) microneedling. These procedures enhance collagen production and address signs of aging. However, their intensity can create wounds comparable to minor burns. With some technologies penetrating the dermis up to 7mm, practitioners may face liability risks when using non-medical-grade products on compromised skin.

Made in Germany under stringent cleanroom conditions, epicite® calm is a  safe and sterile option for treatment-prone skin and surgical wounds. The product is crafted from natural biosynthetic cellulose, ensuring it is non-occlusive, hypoallergenic, and free from fragrances, preservatives, and parabens.

“epicite® CALM will support medical professionals in enhancing their aftercare protocols to meet medical quality standards. We’re looking forward to partnering with distributors in Europe and internationally to help us bring this exceptional product to patients,” said Julia Born, Business Development & Strategic Marketing Manager at Evonik Health Care.

At AMWC in Monaco on March 27-29, Evonik will showcase epicite® CALM at booth M4 on level Pinede, where interested parties can discuss partnership options with the team.

epicite® CALM is the latest addition to JeNaCell’s epicite® family of medical products for advanced wound care and builds on the company’s well-known product portfolio for burn treatment as well as treatment of chronic wounds. Founded in 2012 as a spin-off of the Friedrich Schiller University Jena in Germany, JeNaCell launched its first epicite® product in 2017. Evonik acquired JeNaCell in 2021.

Evonik is a global innovation hub for next-generation biomaterials, working with customers to take their ideas from concept to market. The company provides the industry's most comprehensive portfolio of tailored materials and services for the manufacture of medical devices that open up new possibilities for patient-specific treatment.

Evonik Industries, Jenacell, Jena

Further information:

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.76 billion in 2024 with more than 5,500 employees.  

Disclaimer

In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.